Dostarlimab-gxly

Novartis has entered an option and license agreement with South Korea-based Alteogen Inc. (KOSDAQ: 196170) to develop and commercialize subcutaneous formulations of multiple Novartis biologics using ALT-B4 (berahyaluronidase alfa), the recombinant human hyaluronidase at the core of Alteogen's Hybrozyme platform. If all options are exercised and all milestones achieved, Alteogen said it would be eligible to receive up to USD 3.223 billion, including option exercise fees, development and commercial milestones, and royalties on net sales. The deal is structured as a tiered option-and-license arrangement: Novartis holds multiple options, each of which, upon exercise, converts into an exclusive license to develop and commercialize a specific product using ALT-B4. No upfront payment figure was separately disclosed; the company said the total includes option exercise fees, though individual amounts were not broken out. Royalties on net sales are confirmed but undisclosed. The USD 3.223 billion ceiling is one of Alteogen's largest single ALT-B4 deals to date. The company described it as its fourth licensing agreement signed in 2026. The three preceding 2026 deals — with Tesaro (a GSK subsidiary) for subcutaneous dostarlimab at up to USD 285 million, with Biogen for two biologic products, and with an undisclosed global pharma company for a single asset at up to USD 365 million — each covered one or two products. The Novartis deal's USD 3.223 billion ceiling, benchmarked against the approximately USD 365 million per-product ceiling established in August, implies coverage of a broad product slate. ALT-B4 works by transiently depolymerizing hyaluronan in the subcutaneous extracellular matrix, facilitating dispersion and absorption of co-administered biologics. The technology competes directly with Halozyme Therapeutics' rHuPH20 (ENHANZE platform), which underpins more than a dozen approved subcutaneous products. ALT-B4 received its first regulatory validation when the US FDA approved a subcutaneous formulation of pembrolizumab using the enzyme in 2025. In June 2026, Alteogen presented preclinical data at the World ADC Summit showing enhanced systemic exposure and an improved safety profile for ALT-B4-enabled subcutaneous ADC delivery, extending the platform's potential scope. In May 2026, the US Patent Trial and Appeal Board rejected Halozyme's petition to invalidate Alteogen's recombinant hyaluronidase manufacturing patent, and the European Patent Office indicated intent to grant a substance patent covering ALT-B4 the same month. Three of Alteogen's four 2026 deals followed that resolution. Spot something wrong? Report an issue with this article

GlaxoSmithKline (GSK) Pharmaceuticals has announced its financial results for the first quarter ended June 30, 2026. During the quarter, the company delivered strong growth across both its core and innovative portfolios. The performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence, and a favorable base effect from the comparable period last year. Revenue for the quarter stood at INR 924 crore, up 15 percent Year-on-Year (YoY). Profit After Tax (PAT) increased by 24 percent to INR 253 crore, while EBITDA margins stood at 32 percent. The General Medicines portfolio grew strongly during the quarter, with the top 5 promoted brands outperforming the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Ceftum and T-Bact reinforced their leadership positions in their respective categories, driven by a combination of deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures. The Respiratory portfolio continued to further the management of chronic respiratory diseases with Nucala (mepolizumab) benefitting a large number of patients and Trelegy Ellipta gaining traction through new access pathways. The vaccines business grew through continued leadership in the self-pay private pediatric vaccines market, led by Infanrix Hexa and Fluarix Tetra. In the adult vaccination space, the company’s focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from the healthcare professional community, translating to higher vaccinations with Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted). The oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), has grown significantly since its launch in August last year. Jemperli is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer while Zejula is among the top PARP inhibitors in the maintenance treatment of recurrent ovarian cancer. Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach. Commenting on the results, Bhushan Akshikar, Managing Director (MD), GSK India, said, "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India." The company has made progress in strengthening supply chain resilience through diversified sourcing, enhanced contingency planning and improved end-to-end visibility, substantially mitigating disruptions experienced in recent quarters. Looking ahead, GSK India is preparing for key pipeline launches. Blenrep (belantamab mafodotin), an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. Arexvy, a vaccine to prevent Lower Respiratory Tract Disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk, has received Marketing Authorisation (MA).